Trial Profile
Ergocalciferol +/- risedronic acid for the prevention of osteoporosis in women with Parkinson's disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2011
Price :
$35
*
At a glance
- Drugs Risedronic acid (Primary) ; Ergocalciferol
- Indications Bone resorption; Fracture
- Focus Therapeutic Use
- 27 Dec 2011 New trial record
- 01 Dec 2011 Results published in the Journal of Neurology, Neurosurgery and Psychiatry.